Sophiris Bio Inc. is a late-stage biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH). Source
No articles found.
Five Star Senior Living Inc. is a senior living and healthcare services company. A...
Five Star Senior Living Inc. is a senior living...
CashMD, a startup founded in 2017, brings patients and healthcare providers toget...
CashMD, a startup founded in 2017, brings pati...
Bioptimizers offers health and nutrition supplements.
Bioptimizers offers health and nutrition supple...
Since Aclaris was founded in 2012, our focus has been innovation to help people wi...
Since Aclaris was founded in 2012, our focus ha...
Avenue Therapeutics, Inc., a Fortress Biotech (NASDAQ: FBIO) Company, is a special...
Avenue Therapeutics, Inc., a Fortress Biotech (...
KalVista is a pharmaceutical company focused on the discovery, development and com...
KalVista is a pharmaceutical company focused on...
Prothena Corporation plc (Nasdaq: PRTA) is a clinical-stage neuroscience company f...
Prothena Corporation plc (Nasdaq: PRTA) is a cl...
Join the National Investor Network and get the latest information with your interests in mind.